ABSTRACT
INTRODUCTION
MicroRNAs (miRNAs, miRs) have critical functions in various biological processes such as development, infection, immunity, tumor development and progression [1] . Although numerous miRNAs have been associated with carcinogenesis and the progression of cancer, many of their biological roles remain to be characterized [2] [3] [4] . Members of the miR-200 family are key regulators of epithelial-mesenchymal transition (EMT), an important step in the progression of primary tumors to distant metastasis. For instance, Yeh et al. [5] reported that simultaneous silencing of miR-200c and miR-141 was likely to be responsible for the bile duct metastasis of www.impactjournals.com/oncotarget HCC via EMT activation. However, little is known about the specific role of miR-200b in human hepatocellular carcinoma (HCC) [6, 7] .
The polycomb group protein BMI1 plays a crucial role in the regulation of cell proliferation, stem cell maintenance [8] , tumorigenesis and tumor progression [9] . Overexpression of BMI1 has been observed in several human malignancies, including HCC, and BMI1 acts as an oncogene in some cancer types [9, 10] . We recently demonstrated that BMI1 expression is elevated in HCC and the silencing of the BMI1 gene inhibits the proliferation and invasiveness of human HCC cells [11, 12] . BMI1 is also reportedly a target gene of miR-200b in tongue and prostate cancer [13, 14] . However, the exact regulatory mechanisms of BMI1 expression and its relationship with miR-200b in the initiation and progression of HCC remain to be explored. In this study, we examined the potential roles of miR-200b and BMI1 in the progression of HCC and explored the underlying regulatory mechanisms.
RESULTS

Downregulation of miR-200b in HCC is associated with BMI1 overexpression
The expressions level of miR-200b and BMI1 in HCC tissues and human liver cancer cell lines were analyzed by qPCR. MiR-200b expression was significantly decreased in 83.3% (cohort 1: 30/36; cohort 2: 5/6) of HCC tissues ( Figure 1A ) compared with noncancerous tissues and in the four human liver cancer cell lines (HepG2, SMMC-7721, Bel-7402, Huh7) compared with the normal human liver cell line L02 ( Figure 1D ). By contrast, we detected significant upregulation of BMI1 in 66.7% (cohort 1: 24/36; cohort 2: 4/6) of HCC tissues ( Figure 1B ) and in all four human liver cancer cell lines ( Figure 1D) . Moreover, the expression of miR-200b was negatively correlated with the expression of BMI1 mRNA in HCC tissues in cohort 1 ( Figure 1C ). However, no significant correlations between miR-200b or BMI1 expression and the available clinical parameters of patient cohort 1 were observed (Table S1 ).
BMI1 is a direct target gene of miR-200b and is negatively regulated by miR-200b in human liver cancer cell lines
To validate BMI1 as a bona fide target gene of miR200b, a human BMI1 3'-UTR fragment containing the wild type or mutant type miR-200b-binding sequence was subcloned into the XhoI/NotI site downstream of the firefly luciferase reporter gene in the psiCHECK-2 vector. Interestingly, co-transfection of the miR-200b mimics specifically decreased the luciferase expression of the BMI1-3'-UTR-wt reporter. By contrast, the luciferase activities of the four BMI1-3'-UTR-mut reporters and the psiCHECK-2 control reporter were unaffected by the simultaneous transfection of the miR-200b mimics, which suggests that BMI1 is a direct target gene of miR200b ( Figure 2A ). In addition, the results of the qPCR and western blot analysis demonstrated that transfection with miR-200b mimics significantly reduced the mRNA and protein expression levels of BMI1 in HCC cells (Figure 2B , C and G; Figure S1 ). By contrast, a miR200b inhibitor significantly enhanced the expression of BMI1 in HCC cells (Figure 2D , E and G; Figure S1 ). Accordingly, the silencing of the BMI1 gene by siRNA transfection in HCC cells resulted in the downregulation of endogenous BMI1 mRNA and protein levels compared with the negative control (Figure 2F and G; Figure S1 ). Next, cell cycle distribution analysis was performed to investigate whether the effects of miR-200b and BMI1 are mediated by cell cycle regulation. Upon treatment with aphidicolin (5 µM), more than 70% of the cells underwent growth arrest at the G0/G1 stage, and no difference was observed among the six groups in terms of cell cycle distribution. After removal of aphidicolin, transfection of miR-200b mimics or BMI1 siRNA triggered significant growth arrest of HCC cells at G1 phase, suggesting that the G1/S cell cycle transition is slowed by miR-200b-mediated BMI1 silencing ( Figure 3D ; Figures S5 and S6 ). One function of the retinoblastoma protein (Rb) is to prevent excessive cell growth by preventing the progression from G1 to S phase of the cell cycle [15] . We observed that miR-200b mimics or BMI1-siRNAtransfection induced a higher rate of Rb dephosphorylation compared with the controls, consistent with the accumulation of cells in G1 phase ( Figure 3E ; Figure S6 ).
We previously demonstrated that knockdown of BMI1 inhibits the invasive properties of human HCC cells [11] . Because miR-200b is a negative regulator of BMI1, we performed an in vitro cell invasion assay to further determine if miR-200b affects cell invasion. As expected, transfection of HCC cells with miR200b mimics or BMI1-siRNA notably suppressed their invasion ability compared with normal control cells ( Figure 3F ; Figures S7 and S8) . Collectively, the above results suggest that miR-200b not only suppresses growth but also inhibits the invasiveness of tumor cells by directly targeting BMI1.
Exogenous overexpression of miR-200b suppresses tumorigenicity in vivo
The in vitro findings were confirmed using animal models. Nude mice were injected subcutaneously in 
DISCUSSION
We previously determined that miR-101 can inhibit the progression of HCC via downregulation of enhancer of zeste homolog 2 (EZH2; polycomb group protein) [2] .
In this study, we demonstrated that the tumor suppressor miR-200b represses HCC progression by directly targeting the oncogene BMI1. Furthermore, our data indicate that miR-200b is partially silenced by DNA hypermethylation.
Accumulating evidence suggests that miRNAs regulate a variety of physiological functions via the regulation of their target gene-related signaling pathways [16] . The previously identified tumor suppressor miR200b modulates tumor development and malignant progression by downregulating its target genes. Sun and colleagues [13] Emerging evidence suggests that EMT can promote cancer cell motility and plasticity and can fuel both tumor initiation and metastatic spread [17] . The miR-200 family plays a vital role in tumor suppression through the inhibition of EMT [6, 7] . MiR-200b can restrain the process of EMT and consequently inhibit EMT-mediated tumor invasion and metastasis. MiR-200b is therefore considered an important oncomir in many types of cancer [18] [19] [20] . Here, we demonstrated that miR-200b not only suppresses invasion but also inhibits the growth of HCC cells via the direct targeting of BMI1. Ectopic overexpression of miR-200b also dramatically inhibited HCC cell proliferation and colony formation, thereby contributing to the delay in HCC progression. These effects may be mediated by the inhibition of the BMI1 oncogene, which would lead to a higher rate of Rb dephosphorylation and the accumulation of cells in G1 phase. In addition, tumor growth inhibition was also observed in vivo in HepG2 and SMMC-7721 xenografts.
An increasing number of miRNAs have been linked to chemotherapeutic drug induced apoptosis [21] . We previously demonstrated that forced expression of miR-101 can sensitize HCC cells to chemotherapeutic treatment by directly targeting the EZH2 oncogene [2] . In the present study, miR-200b-mediated BMI1 silencing sensitized HCC cells to 5-FU-induced apoptosis, whereas an inhibitor of miR-200b antagonized the pro-apoptotic effect, suggesting that miR-200b may increase chemotherapeutic druginduced cytotoxicity.
The crucial role of miR-200b and its target gene BMI1 in the progression of HCC prompted us to www.impactjournals.com/oncotarget further explore the mechanisms underlying the aberrant expression of miR-200b in HCC. Recent studies have demonstrated that DNA hypermethylation of CpG islands within gene promoter can downregulate tumor suppressor genes in human cancers [22] . He et al. [23] reported that DNA methylation plays an important and complex role in the regulation of miRNA expression in HCC. Our 
In summary, our results indicate that miR-200b is partially silenced by DNA hypermethylation and can repress tumor progression by directly targeting BMI1 in HCC. Our study suggests that miR-200b plays an important role in the progression of HCC and may be a potential therapeutic target in cancer progression. Tables S1 and S2 .
MATERIALS AND METHODS
Patients and tissue samples
Cell culture
Human HCC cell lines HepG2, SMMC-7721, Bel-7402, Huh7, and normal liver cell line L02 were obtained from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). SMMC-7721 and BEL-7402 cell lines were cultured in RPMI 1640 medium (Gibco, Life Technologies Corporation, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (Biological Industries, Kibbuiz, Israel). HepG2, Huh7 and L02 were cultured in DMEM medium (Gibco) supplemented with 10% fetal bovine serum (Biological Industries). All cells were maintained at 37°C in a humidified incubator containing 5% CO 2 .
The bioinformatics of miR-200b
The predicted targets of miR-200b and their target sites were analyzed usingmiRanda (http://www. microrna.org/microrna/home.do), miRBase (http://www. mirbase.org/) and TargetScan (http://www.targetscan. org/). We search and obtain the 2kb DNA gene sequence of 5'-upstream of miR-200b by bioinformatics genome database UCSC (http://genome.ucsc.edu/) and one CpG island were found (Criteria used: Island size > 100 bp, GC Percent > 50.0%, Obs/Exp > 0.6). We carry out promoter search by means of ITFP (http://itfp.biosino.org/itfp/ TFSearcher/index.jsp).
RNA preparation and quantitative real-time PCR (qPCR) assay
RNA was extracted and qPCRwas conducted as already described [12] .The sequences of all primers are provided in Table S3 .
Western blot analysis
Western blot analysis was performed as described in our previous study [12] , with the following primary antibodies: anti-BMI1 (1:400; Abcam, Cambridge, MA, USA), anti-phosphorylated retinoblastoma (pRb; 1:1000; Cell Signaling Technology, Damvers, MA, USA), antiCleaved PARP (poly adenosine diphosphate ribose polymerase; 1:500; Cell Signaling Technology) or anti-β-tubulin (1:2000; Cell Signaling Technology).
Transfection
All miRNA mimics, inhibitors and BMI1 siRNAs were obtained from GenePharma (Shanghai, China) and their sequences were shown in Table S4 . Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) was used as a transfection reagent, and transfections were performed according to manufacturers' recommendations (described in details elsewhere [12] ).
Vector construction and luciferase reporter assay
The region of human BMI1-3'-untranslated region (UTR; bases 8334 to 10276) containing three putative miR-200b-binding sites (miRanda; Figure S12 ). A wild type (wt) and four mutant type (mut) 3'-UTR segments of human BMI1 mRNA were amplified and subcloned into XhoI and NotI restriction sites downstream of the luciferase reporter gene in the psiCHECK-2 vector (Applied Biosystems, Foster, CA, USA). Primer sequences for amplification of BMI1-3'-UTR are listed in Table S5 (BMI1-3'-UTR-mut4: three putative miR-200b-binding sites are all mutated by double mutation). All clones were subjected to sequencing to verify the correctness of the nucleotide sequences. Luciferase activities were assayed using a Dual-Luciferase Reporter Assay system (Promega, Madison, WI, USA) according to the manufacturer's instructions.
Generation of stably-transfected HCC cell lines for constitutive miR-200b and BMI1-shRNA expression
Human miR-200b mimics/inhibitors and BMI1-shRNA oligoswere designed and cloned into the pGLV3/ H1/GFP+Purolentiviral vector (between the BamHI and EcoRI site). Oligos and primer sequences for generation of Lentiviral-miR-200b/BMI1-shRNA are listed in Table  S6 . HepG2 and SMMC-7721 cells were infected with our newly recombinant lentiviruses and negative control. Virus-containing media were changed with fresh culture medium after 12 -24 h of infection. All cells were exchanged with fresh medium containing puromycin to select for stably transfected cells. The transduction efficiency and stability of the transfectants were monitored by FACS analysis ( Figure S13 ). The BMI1 protein expressions in these cells were checked by western blot analysis.
Cell viability, colony formation, cell cycle, cell invasion, apoptosis analyses and tumorigenicity assays in nude mice Cell viability, colony formation, cell cycle, cell invasion, apoptosis analyses and tumorigenicity assays in nude mice were performed as described in the Supplementary Materials and Methods.
DNA extraction, methylation-specific PCR (MSP) and bisulfite sequencing PCR (BSP)
Genomic DNA from patient samples and cell lines was isolated with Easypure Genomic DNA kit (TransGen Biotech, Beijing, China). MSP was conducted by simultaneous use of primers for methylated and unmethylated forms (Table S3 ). The BSP primer (Table  S3) was designed by Methprimer. Amplified PCR Products were purified and cloned into pMD19-T (TaKaRa). Ten clones of the selected pair of tumor and adjacent nontumor tissue samples and each cell were sequenced, respectively. Percentage of methylation was calculated by QUMA (http://quma.cdb.riken.jp/top/index.html) [24] .
5-Azacytidine (5-AzaC) demethylation treatment
For demethylation studies, HepG2 and SMMC-7721 cells were treated with the indicated concentrations of 5-AzaC (Sigma-Aldrich, St. Louis., MO, USA) for 36 h. The cells were then harvested for qPCR and western blot analysis.
Statistical analysis
All statistical analysis was performed using SPSS for Windows (version 17.0, SPSS, Chicago, IL, USA). All experiments for cell cultures were carried out independently at least three times and in triplicate each time. All data were expressed as mean ± standard deviation (SD) unless otherwise indicated. We determined the significance of differences in the human HCC data using χ2 test and Pearson's correlation test, in the in vitro data using Student's t test, and in the in vivo data using the Mann-Whitney U test. In all cases, p values < 0.05 were considered statistically significant.
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